Precision medicine for KRAS wild-type pancreatic adenocarcinomas

KRAS mutation is the most common molecular alteration in pancreatic adenocarcinoma (PDAC), and around 10% of patients harbor KRAS wild-type tumors (KRAS ). A retrospective chart review of clinical/molecular data was performed including all PDAC patients with a determined KRAS status (tumor molecular profiling on tissue or liquid biopsy). 342 patients were included with 54 KRAS PDAC (16%) compared to 288 patients with KRAS PDAC. Median age was 61 years [IQR:54.0;67.0] and 164 pts (48%) were female. At diagnosis, KRAS patients (63%) were more frequently diagnosed at a non-metastatic stage compared to KRAS patients (41%) (p = 0.003). Regarding metastatic sites, liver was less frequent in KRAS (39%, p